CU20150174A7 - Método para generar una composición farmacéutica purificada de un complejo de radionúclido emisor alfa - Google Patents
Método para generar una composición farmacéutica purificada de un complejo de radionúclido emisor alfaInfo
- Publication number
- CU20150174A7 CU20150174A7 CUP2015000174A CU20150174A CU20150174A7 CU 20150174 A7 CU20150174 A7 CU 20150174A7 CU P2015000174 A CUP2015000174 A CU P2015000174A CU 20150174 A CU20150174 A CU 20150174A CU 20150174 A7 CU20150174 A7 CU 20150174A7
- Authority
- CU
- Cuba
- Prior art keywords
- complex
- generating
- radionucclid
- issuer
- alfa
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000011230 binding agent Substances 0.000 abstract 3
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Dispersion Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Saccharide Compounds (AREA)
- Extraction Or Liquid Replacement (AREA)
Abstract
Un método para generar una solución purificada de por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto una solución del complejo de radionúclido emisor alfa y por lo menos un núclido hijo que tiene por lo menos un ligante selectivo para los núclidos hijos y subsiguientemente separar la solución del ligante selectivo. También, un método para preparar por lo menos un radionúclido hijo de una solución que comprende por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto la solución que tiene por lo menos un ligante selectivo para los núclidos hijos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1310028.4A GB201310028D0 (en) | 2013-06-05 | 2013-06-05 | Pharmaceutical preparation |
| PCT/EP2014/061743 WO2014195423A1 (en) | 2013-06-05 | 2014-06-05 | Pharmaceutical preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20150174A7 true CU20150174A7 (es) | 2016-06-29 |
| CU24535B1 CU24535B1 (es) | 2021-07-02 |
Family
ID=48805787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2015000174A CU24535B1 (es) | 2013-06-05 | 2014-06-05 | Método para generar una solución purificada de un isótopo de torio emisor alfa |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US20160114063A1 (es) |
| EP (1) | EP3003401B1 (es) |
| JP (1) | JP6580559B2 (es) |
| KR (1) | KR102321763B1 (es) |
| CN (1) | CN105592863B (es) |
| AP (1) | AP2015008894A0 (es) |
| AU (1) | AU2014276885B2 (es) |
| BR (1) | BR112015030298A2 (es) |
| CA (1) | CA2914278C (es) |
| CL (1) | CL2015003554A1 (es) |
| CR (1) | CR20150642A (es) |
| CU (1) | CU24535B1 (es) |
| DK (1) | DK3003401T3 (es) |
| DO (1) | DOP2015000294A (es) |
| EA (1) | EA201501174A1 (es) |
| ES (1) | ES2782624T3 (es) |
| GB (1) | GB201310028D0 (es) |
| HR (1) | HRP20200456T1 (es) |
| IL (1) | IL242704B (es) |
| LT (1) | LT3003401T (es) |
| MA (1) | MA38650B1 (es) |
| MX (1) | MX366028B (es) |
| MY (1) | MY180717A (es) |
| NI (1) | NI201500173A (es) |
| PE (1) | PE20160215A1 (es) |
| PH (1) | PH12015502715A1 (es) |
| PL (1) | PL3003401T3 (es) |
| PT (1) | PT3003401T (es) |
| RS (1) | RS60091B1 (es) |
| SA (1) | SA515370233B1 (es) |
| SG (1) | SG11201509856RA (es) |
| SI (1) | SI3003401T1 (es) |
| TN (1) | TN2015000527A1 (es) |
| UA (1) | UA120352C2 (es) |
| WO (1) | WO2014195423A1 (es) |
| ZA (1) | ZA201600027B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
| GB201600161D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope purification method |
| MX2022006638A (es) | 2019-12-05 | 2022-07-19 | Sciencons AS | Producción de 212pb altamente purificados. |
| US20240108766A1 (en) | 2021-01-22 | 2024-04-04 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
| NO347755B1 (en) * | 2021-10-21 | 2024-03-18 | Blue Wave Therapeutics Gmbh | Peptide-coupled alginate gels comprising radionuclides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5749042A (en) * | 1997-01-28 | 1998-05-05 | Battelle Memorial Institute | Bismuth generator method |
| GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| US8481694B2 (en) * | 2009-04-29 | 2013-07-09 | Bio-Rad Laboratories, Inc. | Purification of immunoconjugates |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201105298D0 (en) * | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
-
2013
- 2013-06-05 GB GBGB1310028.4A patent/GB201310028D0/en not_active Ceased
-
2014
- 2014-06-05 UA UAA201512920A patent/UA120352C2/uk unknown
- 2014-06-05 WO PCT/EP2014/061743 patent/WO2014195423A1/en not_active Ceased
- 2014-06-05 DK DK14728571.2T patent/DK3003401T3/da active
- 2014-06-05 TN TN2015000527A patent/TN2015000527A1/en unknown
- 2014-06-05 PT PT147285712T patent/PT3003401T/pt unknown
- 2014-06-05 JP JP2016517608A patent/JP6580559B2/ja not_active Expired - Fee Related
- 2014-06-05 SG SG11201509856RA patent/SG11201509856RA/en unknown
- 2014-06-05 MA MA38650A patent/MA38650B1/fr unknown
- 2014-06-05 PE PE2015002566A patent/PE20160215A1/es unknown
- 2014-06-05 CA CA2914278A patent/CA2914278C/en active Active
- 2014-06-05 EA EA201501174A patent/EA201501174A1/ru unknown
- 2014-06-05 ES ES14728571T patent/ES2782624T3/es active Active
- 2014-06-05 CU CU2015000174A patent/CU24535B1/es unknown
- 2014-06-05 AU AU2014276885A patent/AU2014276885B2/en not_active Ceased
- 2014-06-05 SI SI201431535T patent/SI3003401T1/sl unknown
- 2014-06-05 CN CN201480044621.8A patent/CN105592863B/zh not_active Expired - Fee Related
- 2014-06-05 MY MYPI2015704399A patent/MY180717A/en unknown
- 2014-06-05 KR KR1020157036893A patent/KR102321763B1/ko not_active Expired - Fee Related
- 2014-06-05 LT LTEP14728571.2T patent/LT3003401T/lt unknown
- 2014-06-05 BR BR112015030298A patent/BR112015030298A2/pt active Search and Examination
- 2014-06-05 AP AP2015008894A patent/AP2015008894A0/xx unknown
- 2014-06-05 EP EP14728571.2A patent/EP3003401B1/en active Active
- 2014-06-05 MX MX2015016726A patent/MX366028B/es active IP Right Grant
- 2014-06-05 US US14/896,424 patent/US20160114063A1/en not_active Abandoned
- 2014-06-05 HR HRP20200456TT patent/HRP20200456T1/hr unknown
- 2014-06-05 PL PL14728571T patent/PL3003401T3/pl unknown
- 2014-06-05 RS RS20200349A patent/RS60091B1/sr unknown
-
2015
- 2015-11-22 IL IL242704A patent/IL242704B/en active IP Right Grant
- 2015-12-03 SA SA515370233A patent/SA515370233B1/ar unknown
- 2015-12-04 NI NI201500173A patent/NI201500173A/es unknown
- 2015-12-04 DO DO2015000294A patent/DOP2015000294A/es unknown
- 2015-12-04 CR CR20150642A patent/CR20150642A/es unknown
- 2015-12-04 CL CL2015003554A patent/CL2015003554A1/es unknown
- 2015-12-04 PH PH12015502715A patent/PH12015502715A1/en unknown
-
2016
- 2016-01-04 ZA ZA2016/00027A patent/ZA201600027B/en unknown
-
2021
- 2021-05-04 US US17/307,857 patent/US20220023449A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18053055A (es) | Agonista triple de receptores de glucagón/glp-1/gip | |
| CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
| MX2018009876A (es) | Encapsulamiento y desencapsulamiento de medios. | |
| NI201700167A (es) | Terapias combinadas para hemo malignidades con anticuerpos anti-cd38 e inhibidores de survivina | |
| MX2018005551A (es) | Anticuerpos que se unen especificamente a pd-1, y sus usos. | |
| UY35589A (es) | Compuesto peptídico | |
| ECSP17010156A (es) | Compuestos aminopirimidinilo como inhibidores jak | |
| CR20150049A (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
| CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| PT3456717T (pt) | Derivado de 4,6-diamino-quinolina-3-carbonitrilo como modulador do cancro da tiróide de osaka (cot) para o tratamento de doenças inflamatórias | |
| CL2017003163A1 (es) | Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| EA201792612A1 (ru) | 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot | |
| AR097627A1 (es) | Métodos y dispositivos para la codificación conjunta de canales múltiples | |
| CL2018000371A1 (es) | Complejos de anillos macrocíclicos de pentaaza que poseen biodisponibilidad oral. | |
| CR20150642A (es) | Preparado farmaceutico | |
| CU20160069A7 (es) | Sistema multiparticulado para administrar drogas | |
| BR112017002139A2 (pt) | ?método para preparar um composto? | |
| MX2016007592A (es) | Composicion que comprende agente beneficioso y solvente aprotico. | |
| UY35823A (es) | Profármacos de antagonista de nmda | |
| MX2019015603A (es) | Encapsulamiento de guia de servicios. | |
| FR3025354B1 (fr) | Creation d'isotopes par reactions nucleaires en chaine | |
| MX2016016417A (es) | Autorizacion de union de instancias de cadena de transformacion. | |
| PL407052A1 (pl) | Sposób utwardzania żywicy epoksydowej z wykorzystaniem bis(heptaizooktyloglinosilseskwioksanu) | |
| CO7141421A2 (es) | Formulación farmacéutica que tiene estabilidad mejorada |